Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(1;11)(p32;q23) KMT2A/EPS15

Written2010-09Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9807/3 Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged
ICD-Morpho 9811/3 B lymphoblastic leukaemia/lymphoma, NOS
ICD-Morpho 9813/3 B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
ICD-Morpho 9989/3 Myelodysplastic syndrome, unclassifiable
Atlas_Id 1046
 
  t(1;11)(p32;q23) G-banding - Courtesy Melanie Zenger and Claudia Haferlach (left), and Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap,UW Cytogenetic Services.

Clinics and Pathology

Disease Acute lymphoblastic leukaemia (ALL), biphenotypic acute leukaemia (BAL), acute myeloid leukaemia (AML), and myelodysplastic syndrome (MDS).
Note 36 cases are available to date (Kaneko et al.,1986; Gregoire et al., 1987; Selypes and Laszlo, 1987; Hagemeijer et al., 1987; Hayashi et al., 1989; Raimondi et al., 1989; Shippey et al., 1989; Pui et al., 1990; Lampert et al., 1991; Abshire et al., 1992; Bernard et al., 1994; Felix et al., 1995; Felix et al., 1998; Harrison et al., 1998; Laughlin et al., 1998; Pinto et al., 1998; Secker-Walker et al., 1998; Nakamura et al., 2000; von Bergh et al., 2000; Chessells et al., 2002; Kim et al., 2002; Tsujioka et al., 2003; Douet-Guilbert et al., 2005; Sagawa et al., 2006; Jeon and Yi, 2009; de Braekeleer et al., 2010; Shinohara et al., 2010); we have excluded from this review a case of t(1;6;11)(p32;q21;q23) in a T-cell lymphoma referred as "T-CLL", as it probably represents another entity (Mecucci et al., 1988). We must also keep in mind that some of the t(1;11)(p32;q23) above harvested may not all share the common genetic event 5' MLL - 3' EPS15: a case of t(1;11)(p32;q23), del(5q), +8 in a patient with therapy-related leukaemia has recently been described without MLL rearrangement (Yamamoto et al., 2010). There are also 3 paediatric cases (2 ALLs, 1 AML) of MLL/EPS15 translocation which were not included in this study, due to the lack of clinical data (Meyer et al., 2006).
Phenotype / cell stem origin About half cases were ALLs and half cases AMLs. There were 17 ALLs, (mainly CD19+, CD10-) 2 biphenotypic leukaemias, 15 AMLs (of which were three M4-AMLs and nine M5-AMLs), and two MDS. There were at least nine cases of secondary leukaemia (and also 3 cases of "relapse", but each time with a different karyotype; e.g. a M1-AML with the classical t(8;21)(q22;q22) relapsed 16 months later with a t(1;11) as the sole anomaly (Hayashi et al., 1989)). The delay before onset of the secondary leukaemia -including the so-called relapses- was very similar, from a case to another, with a median of 16-21 months (range 12-24 months), if we exclude a case with an interval of 46 years after nuclear bombing (Nakamura et al., 2000). The previous disease was a haematological malignancy in seven cases (MDS, AML, ALL, multiple myeloma, non Hodgkin lymphoma (NHL)), a soft tissue tumour in three cases (primitive neuroectodermal tumour (PNET), PEComa, osteogenic sarcoma), and a breast cancer. The second leukaemia was an ALL in 6 cases, and a myeloid leukaemia (MDS or AML) in 6 cases.
Epidemiology There was 12 male and 23 female patients (non significant: epsilon = 1.86, 0.07 < p < 0.06). However, while there was 8 male and 10 female patients in myeloid cases, there was only 3 male patients and 13 female patients with ALL (chi2 = 6.25 p < 0.02). Patients median age was 4 years (range 0-76 years); thirteen cases (38%) were infant cases (at or under 1 year of age), seven cases (20%) were between 1 and 10 years, three cases between 10 and 16, and twelve cases (1/3) were adult cases. Median age was 7 years in myeloid cases versus 1 year in lymphoid cases (ranges were 0.2-76 years and 0-63 years respectively, but with 5 cases and 1 case above 60 years respectively). About half of female cases (11/23), but only 2 of 11 male cases were congenital leukaemias (diagnosis at or before one year of age), although the ranges were similar, with cases above the sixties in both genders this is not statistically significant (chi2 = 2.77, 0.05 < p < 0.10). Median age in female patients was 2-3 years vs 7 years for male patients, ranges were similar.
Clinics A high white blood cound was noted in 9 of 11 documented cases.
 
Prognosis Median survival was 15 months (see figure), with a very few long survivors (a patient was still alive 140 months after diagnosis (Chessells et al., 2002)). Median survival for female patients was 28 months, vs 11 months in male patients; Survival was significantly different according to the sex of the patients (chi2 = 4,66, p < 0.05, log rang test at 16 months). Survival curves for ALL and AML cases cross each other, with a median survival at 28 months for ALL cases and only 14 months for AML cases, but with no statistical significance. There was no correlation between age of the patient and survival. All the same and more surprisingly, the few patients with a secondary leukaemia with data on survival (n=6) did not seem to behave more badly than de novo cases. Also, the presence or the absence of chromosomal anomalies additional to the t(1;11) did not seem to affect the prognosis.

Cytogenetics

Cytogenetics Morphological The t(1;11) was the sole anomaly in 19 of 33 documented cases (57%), equally distributed between ALL and AML cases. There was two complex (three way) translocations: a t(1;11;4)(p32;q23q13;p16) and a t(1;11;10)(p32;q23;q24) (Selypes and Laszlo, 1987; de Braekeleer et al., 2010).
Additional anomalies A trisomy 8 was found in four cases, a trisomy 21 in two cases, a del(5q) or a monosomy 7 in one case each. Karyotypes were similar in ALL and myeloid cases, apart from that trisomy 8 was found as an accompanying anomaly in 3 myeloid and only one lymphoid cases, and that the cases with either del(5q) or -7 were found in myeloid cases. A complex karyotype was present in two myeloid cases.

Genes involved and Proteins

Gene Name EPS15
Location 1p32
Protein A major transcript of 5225 bp produces a 896 amino acids protein from 25 exons; at least 5 other splice variants from 30 different exons. Contains from N-term to C-term: 3 EH (Eps15 Homology) domains (protein-protein interaction modules) with calcium-binding domains (EF hand domains), binding sites to adaptins, SH3 binding site, prolin-rich motifs, ubiquitin interacting motifs (UIM), and a nuclear export signal in C-term. There are also DPF repeats in the C-term third of the protein. Membrane receptor tyrosine kinase signaling inhibition is accomplished by ligand/receptor complexes internalization, subsequent trafficking to lysosomes and ubiquitination. EPS15 is involved in this process. EPS15 has a role in clathrin-mediated endocytosis, and may also have a role in transcriptional regulation (review in van Bergen and Henegouwen, 2009).
Gene Name KMT2A
Location 11q23
Protein A major transcript of 14982 bp produces a 3969 amino acids protein from 36 of the 37 exons. Contains from N-term to C-term a binding site for MEN1, 3 AT hooks (binds to the minor grove of DNA); 2 speckled nuclear localisation signals; 2 repression domains RD1 and RD2: RD1 or CXXC: cystein methyl transferase, binds CpG rich DNA, has a transcriptional repression activity; RD2 recruits histone desacetylases HDAC1 and HDAC2; 3 plant homeodomains (cystein rich zinc finger domains, with homodimerization properties), 1 bromodomain (may bind acetylated histones), and 1 plant homeodomain; these domains may be involved in protein-protein interaction; a FYRN and a FRYC domain; a transactivation domain which binds CBP; may acetylates H3 and H4 in the HOX area; a SET domain: methyltransferase; methylates H3, including histones in the HOX area for allowing chromatin to be open to transcription. MLL is cleaved by taspase 1 into 2 proteins before entering the nucleus: a p300/320 N-term protein called MLL-N, and a p180 C-term protein, called MLL-C. The FYRN and a FRYC domains of native MLL associate MLL-N and MLL-C in a stable complex; they form a multiprotein complex with transcription factor TFIID. General transcription factor; maintains HOX genes expression in undifferentiated cells. Major regulator of hematopoiesis and embryonic development; role in cell cycle regulation.

Result of the chromosomal anomaly

Hybrid gene
Description Variable breakpoint in MLL; fusion of exon 6 to 10 of MLL to exon 2 of EPS15 in most studied cases; in one case the fusion exon of EPS15 was exon 12, but it also retains the coiled-coil domain of EPS15; in other cases, the breakpoint is upstream exon 1.
  
Fusion Protein
Oncogenesis The coiled-coil domains of EPS15 mediates oligomerization, activating MLL, and MLL-EPS15 activates Hox gene expression (So et al., 2003).
  

Bibliography

Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study.
Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm F, Crist WM, Link M, Borowitz M, et al.
Leukemia. 1992 May;6(5):357-62.
PMID 1534389
 
A novel gene, AF-1p, fused to HRX in t(1;11)(p32;q23), is not related to AF-4, AF-9 nor ENL.
Bernard OA, Mauchauffe M, Mecucci C, Van den Berghe H, Berger R.
Oncogene. 1994 Apr;9(4):1039-45.
PMID 8134107
 
Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.
Chessells JM, Harrison CJ, Kempski H, Webb DK, Wheatley K, Hann IM, Stevens RF, Harrison G, Gibson BE; MRC Childhood Leukaemia working party.
Leukemia. 2002 May;16(5):776-84.
PMID 11986937
 
Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature.
De Braekeleer E, Meyer C, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C, Arnaud B, Marschalek R, Ferec C, De Braekeleer M.
Blood Cells Mol Dis. 2010 Apr 15;44(4):268-74. Epub 2010 Mar 4. (REVIEW)
PMID 20206559
 
Rearrangement of the MLL gene in acute myeloblastic leukemia: report of two rare translocations.
Douet-Guilbert N, Morel F, Le Bris MJ, Herry A, Morice P, Bourquard P, Banzakour S, Le Calvez G, Marion V, Berthou C, De Braekeleer M.
Cancer Genet Cytogenet. 2005 Mar;157(2):169-74.
PMID 15721641
 
MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children.
Felix CA, Hosler MR, Slater DJ, Parker RI, Masterson M, Whitlock JA, Rebbeck TR, Nowell PC, Lange BJ.
J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):299-308.
PMID 9703001
 
Karyotype, immunophenotype, and clinical outcome: correlations in childhood acute lymphoblastic leukemia.
Gregoire MJ, Peeters MA, Bene MC, Bordigoni P, Faure G, Gilgenkrantz S, Olive D, Streiff F, Duheille J.
Haematol Blood Transfus. 1987;30:504-8.
PMID 3497848
 
Characterization of the blast cells in acute leukemia with translocation (4;11): report of eight additional cases and of one case with a variant translocation.
Hagemeijer A, van Dongen JJ, Slater RM, van't Veer MB, Behrendt H, Hahlen K, Sizoo W, Abels J.
Leukemia. 1987 Jan;1(1):24-31.
PMID 3118100
 
Ten novel 11q23 chromosomal partner sites. European 11q23 Workshop participants.
Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Mugneret F, Moorman AV, Secker-Walker LM.
Leukemia. 1998 May;12(5):811-22.
PMID 9593286
 
Two karyotypically independent leukemic clones with the t(8;21) and 11q23 translocation in acute myeloblastic leukemia at relapse.
Hayashi Y, Raimondi SC, Behm FG, Santana VM, Kalwinsky DK, Pui CH, Mirro J Jr, Williams DL.
Blood. 1989 May 1;73(6):1650-5. Erratum in: Blood 1989 Aug 15;74(3):1180.
PMID 2713498
 
Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus.
Jeon IS, Yi DY.
Pediatr Hematol Oncol. 2009 Mar;26(2):85-8.
PMID 19322738
 
Clinical and hematologic characteristics in acute leukemia with 11q23 translocations.
Kaneko Y, Maseki N, Takasaki N, Sakurai M, Hayashi Y, Nakazawa S, Mori T, Sakurai M, Takeda T, Shikano T, et al.
Blood. 1986 Feb;67(2):484-91.
PMID 3942833
 
A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic evidence both initially and during follow-up.
Kim HJ, Cho HI, Kim EC, Ko EK, See CJ, Park SY, Lee DS.
Br J Haematol. 2002 Dec;119(4):930-9.
PMID 12472570
 
Chromosome aberrations in acute leukemia in childhood: analysis of 1009 patients
Lampert F, Harbott J, Ritterbach J.
Klin Padiatr. 1991 Jul-Aug;203(4):311-8. [Article in German].
PMID 1834889
 
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ.
J Clin Oncol. 1998 Mar;16(3):1008-12.
PMID 9508184
 
Cytogenetic studies in T-cell malignancies.
Mecucci C, Louwagie A, Thomas J, Boogaerts M, Van Den Berghe H.
Cancer Genet Cytogenet. 1988 Jan;30(1):63-71.
PMID 3257157
 
The MLL recombinome of acute leukemias.
Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, den Boer ML, Pieters R, Ennas MG, Angelucci E, Koehl U, Greil J, Griesinger F, Zur Stadt U, Eckert C, Szczepan'ski T, Niggli FK, Schafer BW, Kempski H, Brady HJ, Zuna J, Trka J, Nigro LL, Biondi A, Delabesse E, Macintyre E, Stanulla M, Schrappe M, Haas OA, Burmeister T, Dingermann T, Klingebiel T, Marschalek R.
Leukemia. 2006 May;20(5):777-84.
PMID 16511515
 
Chromosome 1 abnormalities at band 1p32 in two atomic bomb survivors with myelodysplastic syndrome
Nakamura H, Hata T, Tagawa M, Atogami S, Tomonaga M, Sadamori N, Hayashi Y.
Rinsho Ketsueki. 2000 Feb;41(2):152-8. .
PMID 10723246
 
Acute lymphoblastic leukemia with t(1;11)(p32;q23) in a patient treated for osteogenic sarcoma.
Pinto LI, Marczyk FF, Brunetto AL.
Pediatr Hematol Oncol. 1998 Jan-Feb;15(1):93-5.
PMID 9509513
 
Myeloid neoplasia in children treated for solid tumours.
Pui CH, Hancock ML, Raimondi SC, Head DR, Thompson E, Wilimas J, Kun LE, Bowman LC, Crist WM, Pratt CB.
Lancet. 1990 Aug 18;336(8712):417-21.
PMID 1974952
 
Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23.
Raimondi SC, Peiper SC, Kitchingman GR, Behm FG, Williams DL, Hancock ML, Mirro J Jr.
Blood. 1989 May 1;73(6):1627-34.
PMID 2496771
 
The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.
Rogaia D, Grignani F, Carbone R, Riganelli D, LoCoco F, Nakamura T, Croce CM, Di Fiore PP, Pelicci PG.
Cancer Res. 1997 Mar 1;57(5):799-802.
PMID 9041173
 
Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop.
Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB.
Leukemia. 1998 May;12(5):840-4.
PMID 9593290
 
A new translocation t(1;4;11) in congenital acute nonlymphocytic leukemia (acute myeloblastic leukemia).
Selypes A, Laszlo A.
Hum Genet. 1987 May;76(1):106-8.
PMID 3471701
 
A novel MLL-AF1p/Eps15 fusion variant in therapy-related acute lymphoblastic leukemia, lacking the EH-domains.
Shinohara A, Ichikawa M, Ueda K, Takahashi T, Hangaishi A, Kurokawa M.
Leuk Res. 2010 Feb;34(2):e62-3. Epub 2009 Aug 8.
PMID 19665789
 
Isochromosome 9q in acute lymphoblastic leukemia: a new non-random finding.
Shippey CA, Lawlor E, Secker-Walker LM.
Leukemia. 1989 Mar;3(3):195-9.
PMID 2918757
 
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
So CW, Lin M, Ayton PM, Chen EH, Cleary ML.
Cancer Cell. 2003 Aug;4(2):99-110.
PMID 12957285
 
The interaction between EEN and Abi-1, two MLL fusion partners, and synaptojanin and dynamin: implications for leukaemogenesis.
So CW, So CK, Cheung N, Chew SL, Sham MH, Chan LC.
Leukemia. 2000 Apr;14(4):594-601.
PMID 10764144
 
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Tsujioka T, Wada H, Yamamori S, Otsuki T, Suemori S, Kondo T, Nakanishi H, Suetsugu Y, Mikami M, Sugihara T.
Int J Hematol. 2003 Dec;78(5):439-42.
PMID 14704037
 
Therapy-related myelodysplastic/myeloproliferative neoplasms with del(5q) and t(1;11)(p32;q23) lacking MLL rearrangement.
Yamamoto K, Katayama Y, Shimoyama M, Matsui T.
Intern Med. 2010;49(11):1031-5. Epub 2010 Jun 1.
PMID 20519822
 
Eps15: a multifunctional adaptor protein regulating intracellular trafficking.
van Bergen En Henegouwen PM.
Cell Commun Signal. 2009 Oct 8;7:24.
PMID 19814798
 
A DNA probe combination for improved detection of MLL/11q23 breakpoints by double-color interphase-FISH in acute leukemias.
von Bergh A, Emanuel B, van Zelderen-Bhola S, Smetsers T, van Soest R, Stul M, Vranckx H, Schuuring E, Hagemeijer A, Kluin P.
Genes Chromosomes Cancer. 2000 May;28(1):14-22.
PMID 10738298
 

Citation

This paper should be referenced as such :
Huret, JL
t(1;11)(p32;q23)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(6):529-532.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/t0111p32q23ID1046.html


Other genes implicated (Data extracted from papers in the Atlas) [ 2 ]

Genes EPS15 KMT2A

Translocations implicated (Data extracted from papers in the Atlas)

 t(1;11)(p32;q23) KMT2A/EPS15

External links

KMT2A (11q23.3) EPS15 (1p32.3)

KMT2A (11q23.3) EPS15 (1p32.3)

Mitelman databaset(1;11)(p32;q23) [Case List]    t(1;11)(p32;q23) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9807/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9811/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9813/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9989/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
COSMIC_fusionKMT2A/EPS15 KMT2A (11q23.3) EPS15 (1p32.3)   [fusion1998]   [fusion1999]   [fusion2002]   [fusion2003]   [fusion2004]   [fusion2007]   [fusion2008]  
TICdbKMT2A/EPS15  KMT2A (11q23.3) EPS15 (1p32.3)
 
Disease databaset(1;11)(p32;q23) KMT2A/EPS15
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:54:17 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.